TickerTain
$SPCX····$NVDA····$MSFT····$GOOGL····$ANTHROPIC·$TSLA····$CRWV····$NBIS····$HIMS····$TSM····$ASML····$FIGURE·$LYFT····$UBER····$SNOW····$META····$ELEVENLABS·$CURSOR·$COGNITION·$OPENAI·$AAPL····$RKLB····$XAI·$AMZN····$AMD····$000660.KS····$INTC····
← newsroom
AI Geopolitics & Export Controls · China's state-led biotech plan achieves half-cost, 3x-speed R&D; US should compete not contain
now playing · AI Geopolitics & Export Controls
AI Drug Discoverytailwindscore 9/10albert bourla
AI transforms pharma R&D from target ID to clinical trials but organizational inertia limits adoption
AI models already exceed current utilization in drug discovery (target identification, molecule synthesis, clinical trial design) and manufacturing/commercial, but the bottleneck is organiz…
AI Geopolitics & Export Controlstailwindscore 9/10albert bourla
China's state-led biotech plan achieves half-cost, 3x-speed R&D; US should compete not contain
China's 14th five-year plan executed systematically: built competent FDA, strong IP protection, and fast judiciary — now 8 of top 10 universities in Nature Index are Chinese. They lead in e…
GLP-1 & Metabolic Drugstailwindscore 8/10albert bourla
Monthly dosing and manufacturing scale key differentiators in crowded obesity market
Pfizer's MyThera acquisition targets monthly GLP-1 dosing advantage over weekly Lilly/Novo products, leveraging Pfizer's primary care trial infrastructure, commercial powerhouse, and manufa…
Life Sciences & Drug Developmenttailwindscore 8/10albert bourla
R&D productivity leap via end-to-end integration and commercial-focused portfolio selection
Pfizer doubled phase 2 success rates (20% to 50%+) and achieved 95% regulatory success by merging early/late R&D under single leadership, eliminating handover friction, and shifting portfol…
AI in Healthcaretailwindscore 8/10albert bourla
AI disruption will create new pharma winners and losers within 5 years
Bourla expects AI plus biology advances to radically change standards of care by 2030, disrupting research, manufacturing, commercial, hospitals, physicians, and regulators — the scale of d…